Clinical application of serum biomarkers for ovarian cancer

doi:10.3969/j.issn.1673-8640.2015.08.022

Abstract

Abstract:

Ovarian cancer is the fifth cause of cancer death in women, as well as the cause of deaths in gynecological cancers. Unlike breast cancer, many women die of ovarian cancer because there is no obvious symptom and no screening test in early stages. Nowadays, only a limited number of tumor markers for ovarian cancer has been cleared by U.S. Food and Drug Administration (FDA). In general, tumor marker applications range from diagnosis and curative effect monitoring to predicting prognosis. The article will review the currently available serum markers for ovarian cancer and their clinical application.

Key words: Carbohydrate antigen 125, Human epididymis protein 4, Ovarian cancer

CLC Number:

R446.62

SONG Binbin, PAN Baishen. Clinical application of serum biomarkers for ovarian cancer[J]. Laboratory Medicine, 2015, 30(8): 866-870.

Figures/Tables 1

References 25

[1]	American College of Obstetricians and Gynecologists Committee on Gynecologic Practice.Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer[J]. Obstet Gynecol,2011,117(3):742-746.
[2]	MUNKARAH A,CHATTERJEE M,TAINSKY MA.Update on ovarian cancer screening[J]. Curr Opin Obstet Gynecol,2007,19(1):22-26.
[3]	BUYS SS,PARTRIDGE E,BLACK A,et al.Effect of screening on ovarian cancer mortality: The prostate,lung,colorectal and ovarian (PLCO) cancer screening pandomized controlled trial[J]. JAMA,2011,305(22):2295-2303.
[4]	BALDWIN LM,TRIVERS KF,MATTHEWS B,et al.Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations[J] Ann Intern Med,2012,156(3):182-194.
[5]	BAST RC JR,XU FJ,YU YH,et al.CA 125: the past and the future[J]. Int J Biol Markers,1998,13(4):179-187.
[6]	PARTRIDGE EE,BARNES MN.Epithelial ovarian cancer: prevention,diagnosis,and treatment[J]. CA Cancer J Clin,1999,49(5):297-320.
[7]	中华医学会检验分会,卫生部临床检验中心,中华检验医学杂志编辑委员会. 肿瘤标志物的临床应用建议[J]. 中华检验医学杂志,2012,35(2):103-116.
[8]	KIRCHHOFF C,HABBEN I,IVELL R,et al.A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors[J]. Biol Reprod,1991,45(2):350-357.
[9]	MOORE RG,BROWN AK,MILLER MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol,2008,108(2):402-408.
[10]	HUHTINEN K,SUVITIE P,HIISSA J,et al.Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts[J]. Br J Cancer,2009,100(8):1315-1319.
[11]	TUXEN MK,SÖLÉTORMOS G,DOMBERNOWSKY P.Tumor markers in the management of patients with ovarian cancer[J]. Cancer Treat Rev,1995,21(3):215-245.
[12]	VARTIAINEN J,LEHTOVIRTA P,FINNE P,et al.Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer[J]. Int J Cancer,2001,95(5):313-316.
[13]	DIAMANDIS EP,YOUSEF GM.Human tissue kallikreins: a family of new cancer biomarkers[J]. Clin Chem,2002,48(8):1198-1205.
[14]	DIAMANDIS EP,YOUSEF GM,SOOSAIPILLAI AR,et al.Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma[J]. Clin Biochem,2000,33(7):579-583.
[15]	DONG Y,KAUSHAL A,BUI L,et al.Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas[J]. Clin Cancer Res,2001,7(8):2363-2371.
[16]	LUO LY,KATSAROS D,SCORILAS A,et al.The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis[J]. Cancer Res,2003,63(4):807-811.
[17]	KIM JH,SKATES SJ,UEDE T,et al.Osteopontin as a potential diagnostic biomarker for ovarian cancer[J]. JAMA,2002,287(13):1671-1679.
[18]	SCHORGE JO,DRAKE RD,LEE H,et al.Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer[J]. Clin Cancer Res,2004,10(10):3474-3478.
[19]	JACOBS I,ORAM D,FAIRBANKS J,et al.A risk of malignancy index incorporating CA 125,ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer[J].Br J Obstet Gynaecol,1990,97(10):922-929.
[20]	MOORE RG,JABRE-RAUGHLEY M,BROWN AK,et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass[J]. Am J Obstet Gynecol,2010,203(3):228.e1-e6.
[21]	VAN GORP T,VELDMAN J,VAN CALSTER B,et al.Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses[J]. Eur J Cancer,2012,48(11):1649-1656.
[22]	MENON U,SKATES SJ,LEWIS S,et al.Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer[J]. J Clin Oncol,2005,23(31):7919-7926.
[23]	LU KH,SKATES S,HERNANDEZ MA,et al.A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value[J]. Cancer,2013,119(19):3454-3461.
[24]	MOORE RG,MILLER MC,DISILVESTRO P,et al.Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass[J]. Obstet Gynecol,2011,118(2 Pt 1):280-288.
[25]	UELAND FR,DESIMONE CP,SEAMON LG,et al.Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors[J]. Obstet Gynecol,2011,117(6):1289-1297.

临床应用	单一血清标志物		多因素联合模型
临床应用	CA125	HE4	OVA1	RMI	ROMA	ROCA
一般人群筛查	否	否	否	否	否	是
盆腔肿块良恶性鉴别	是	是	是	是	是	否
治疗监测	是	是	否	否	否	否
复发预测	是	是	否	否	否	否

临床应用	单一血清标志物		多因素联合模型
临床应用	CA125	HE4	OVA1	RMI	ROMA	ROCA
一般人群筛查	否	否	否	否	否	是
盆腔肿块良恶性鉴别	是	是	是	是	是	否
治疗监测	是	是	否	否	否	否
复发预测	是	是	否	否	否	否